PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
1377102-3	1992	Interferon-alpha-2a and interferon-beta also exerted synergistic effects with azidothymidine, but the potentiation was weaker than that by the combination of interferon-gamma and aziodthymidine.	Zidovudine	78-92	interferon alpha 2	Homo sapiens	0-19	
1397675-3	1992	Peak plasma zidovudine concentrations were significantly (P less than 0.05) lower when combined treatment with 150 mg/m2 zidovudine/1.5 MIU interferon-alpha 2a was administered compared with 300 mg/m2 zidovudine alone, or combined 150 mg/m2 zidovudine/3 MIU interferon-alpha 2a.	Zidovudine	12-22	interferon alpha 2	Homo sapiens	140-159	
1397675-3	1992	Peak plasma zidovudine concentrations were significantly (P less than 0.05) lower when combined treatment with 150 mg/m2 zidovudine/1.5 MIU interferon-alpha 2a was administered compared with 300 mg/m2 zidovudine alone, or combined 150 mg/m2 zidovudine/3 MIU interferon-alpha 2a.	Zidovudine	12-22	interferon alpha 2	Homo sapiens	258-277	
1397675-3	1992	Peak plasma zidovudine concentrations were significantly (P less than 0.05) lower when combined treatment with 150 mg/m2 zidovudine/1.5 MIU interferon-alpha 2a was administered compared with 300 mg/m2 zidovudine alone, or combined 150 mg/m2 zidovudine/3 MIU interferon-alpha 2a.	Zidovudine	121-131	interferon alpha 2	Homo sapiens	258-277	
1397675-3	1992	Peak plasma zidovudine concentrations were significantly (P less than 0.05) lower when combined treatment with 150 mg/m2 zidovudine/1.5 MIU interferon-alpha 2a was administered compared with 300 mg/m2 zidovudine alone, or combined 150 mg/m2 zidovudine/3 MIU interferon-alpha 2a.	Zidovudine	121-131	interferon alpha 2	Homo sapiens	258-277	
1397675-3	1992	Peak plasma zidovudine concentrations were significantly (P less than 0.05) lower when combined treatment with 150 mg/m2 zidovudine/1.5 MIU interferon-alpha 2a was administered compared with 300 mg/m2 zidovudine alone, or combined 150 mg/m2 zidovudine/3 MIU interferon-alpha 2a.	Zidovudine	121-131	interferon alpha 2	Homo sapiens	258-277	
9402071-10	1997	The addition of interferon-alpha2a to zidovudine and zalcitabine resulted in transient enhanced decreases in viral load and increased toxicity.	Zidovudine	38-48	interferon alpha 2	Homo sapiens	16-34	
2159992-1	1990	This study was undertaken to calculate the in vivo drug interactions between recombinant human interferon-alpha A/D (rHuIFN-alpha A/D) and 3"-azido-3"-deoxythymidine (AZT) in a quantitative model for retroviral viremia.	Zidovudine	139-165	interferon alpha 2	Homo sapiens	95-115	
2159992-1	1990	This study was undertaken to calculate the in vivo drug interactions between recombinant human interferon-alpha A/D (rHuIFN-alpha A/D) and 3"-azido-3"-deoxythymidine (AZT) in a quantitative model for retroviral viremia.	Zidovudine	167-170	interferon alpha 2	Homo sapiens	95-115	
8399067-1	1993	Previous experimental studies utilizing human recombinant interferon-alpha-2b (IFN alpha-2b) alone or with zidovudine (AZT) to treat established feline leukemia virus (FeLV) infection resulted in a significant reduction in circulating virus throughout a 49-day treatment period.	Zidovudine	107-117	interferon alpha 2	Homo sapiens	58-77	
8820601-1	1995	Previous experimental studies utilizing human recombinant interferon-alpha-2b (IFNalpha-2b) alone or with zidovudine (AZT) to treat established feline leukemia virus (FeLV) infection resulted in a significant reduction in circulating virus throughout a 49-day treatment period.	Zidovudine	118-121	interferon alpha 2	Homo sapiens	58-77	
8399067-1	1993	Previous experimental studies utilizing human recombinant interferon-alpha-2b (IFN alpha-2b) alone or with zidovudine (AZT) to treat established feline leukemia virus (FeLV) infection resulted in a significant reduction in circulating virus throughout a 49-day treatment period.	Zidovudine	119-122	interferon alpha 2	Homo sapiens	58-77